Patel Shreeja, Thompson Dane, Sharshar Mohamed, Crawford James M, Dagher Nabil, Fahmy Ahmed E
Division of Transplant Surgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.
Department of Surgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.
Cureus. 2024 May 20;16(5):e60683. doi: 10.7759/cureus.60683. eCollection 2024 May.
Abernethy syndrome is a rare congenital anomaly characterized by an intrahepatic or extrahepatic portosystemic shunt. Most patients are asymptomatic; however, due to the alteration in, or lack of, a portovenous flow, patients with Abernethy syndrome are at high risk of developing sequelae of liver failure. Once these complications develop, the only definitive treatment is transplantation. Patients with Abernethy syndrome are also at a higher risk of developing benign and malignant liver lesions, including hepatic adenomas. Here, we describe the first case of deceased donor liver transplantation as a treatment for a patient with type 1 Abernethy syndrome complicated by large, unresectable hepatic adenoma, found to have focal hepatocellular carcinoma on pathologic examination. Our male patient was found to have elevated liver enzymes at age 33, during a routine outpatient medical appointment. Despite being asymptomatic, his history of prior liver resection prompted CT imaging, which revealed two large liver lesions concerning for hepatic adenomas. When surveillance imaging showed a significant growth of the liver lesions, biopsy was pursued, which confirmed a diagnosis of hepatic adenomas. However, given the size of these lesions, resection was not a viable option for the patient. Instead, the patient underwent liver transplantation at age 41, which he tolerated well. Our case demonstrates the utility of deceased donor liver transplantation as a treatment for patients with Abernethy syndrome complicated by unresectable adenomas.
阿伯内西综合征是一种罕见的先天性异常,其特征为肝内或肝外门体分流。大多数患者无症状;然而,由于门静脉血流改变或缺乏门静脉血流,阿伯内西综合征患者发生肝衰竭后遗症的风险很高。一旦出现这些并发症,唯一的确定性治疗方法是移植。阿伯内西综合征患者发生包括肝腺瘤在内的良性和恶性肝脏病变的风险也更高。在此,我们描述首例脑死亡供体肝移植治疗1型阿伯内西综合征合并巨大、无法切除肝腺瘤且病理检查发现局灶性肝细胞癌的患者。我们的男性患者在33岁常规门诊就诊时发现肝酶升高。尽管无症状,但他既往肝切除史促使进行CT成像,结果显示两个肝脏大病变,怀疑为肝腺瘤。当监测成像显示肝脏病变显著增大时,进行了活检,确诊为肝腺瘤。然而,鉴于这些病变的大小,手术切除对该患者并非可行选择。相反,该患者在41岁时接受了肝移植,耐受性良好。我们的病例证明了脑死亡供体肝移植作为治疗阿伯内西综合征合并无法切除腺瘤患者的有效性。